WILD-TYPE TRANSTHYRETIN-RELATED (ATTR)AMYLOIDOSIS

Clinical trials for WILD-TYPE TRANSTHYRETIN-RELATED (ATTR)AMYLOIDOSIS explained in plain language.

Never miss a new study

Get alerted when new WILD-TYPE TRANSTHYRETIN-RELATED (ATTR)AMYLOIDOSIS trials appear

Sign up with your email to follow new studies for WILD-TYPE TRANSTHYRETIN-RELATED (ATTR)AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Early trial tests drug for debilitating nerve damage in rare heart condition

Disease control Ongoing

This small, early-phase study is testing whether the drug patisiran can help control nerve damage in people with wild-type ATTR amyloidosis, a rare condition where abnormal proteins build up in the body. Ten participants with nerve symptoms will receive patisiran infusions every …

Matched conditions: WILD-TYPE TRANSTHYRETIN-RELATED (ATTR)AMYLOIDOSIS

Phase: EARLY_PHASE1 • Sponsor: Austin Neuromuscular Center • Aim: Disease control

Last updated Mar 30, 2026 14:33 UTC

WILD-TYPE TRANSTHYRETIN-RELATED (ATTR)AMYLOIDOSIS

Get alerted when new WILD-TYPE TRANSTHYRETIN-RELATED (ATTR)AMYLOIDOSIS trials appear

Early trial tests drug for debilitating nerve damage in rare heart condition